The value of anti-Helicobacter pylori IgG antibodies in establishing eradication of infection in children.

The aim of this study was to evaluate the performance of anti-Helicobacter pylori (H. pylori) IgG antibodies in monitoring eradication of infection in children. Forty-seven H.

Colchicine enhances intestinal permeability in patients with familial Mediterranean fever.

Objective: Colchicine therapy is complicated by frequent gastrointestinal adverse effects.

Methods: We compared intestinal permeability in 21 patients with familial Mediterranean fever on long-standing colchicine therapy (mean 5.8 years) and significant gastrointestinal complaints and 12 untreated patients and 14 healthy volunteers.

Serum pepsinogen I in childhood Helicobacter pylori gastritis: its relation to mucosal peptic activity.

Serum pepsinogen I (PG I) levels are raised in children with Helicobacter pylori gastritis. To ascertain if this is due to increased production or to increased secretion of pepsin by chief cells, we measured mucosal peptic activity in antrum and gastric body mucosal homogenates and correlated it to serum PG I levels in 122 children with and without H. pylori gastritis.

Basal and activated intracellular calcium ion concentrations in mononuclear cells of Alzheimer's disease and unipolar depression.

We present the results of a case control study on the concentration of intracellular calcium [Ca+2]i in peripheral blood mononuclear cells (PBMC) of patients with Alzheimer's disease (AD), major affective disorder unipolar type (DEP), and elderly controls. We used the fluorescent dye Quin-2 to measure intracellular calcium concentration in PBMC both in their basal resting state [Ca+2]b and after activation [Ca+2]a with phytohemagglutinin (PHA). The [Ca+2]b and [Ca+2]a values in PBMC of AD patients were significantly higher than those of the elderly controls and of the DEP patients.

Colchicine induces enhanced intestinal permeability in the rat.

Intestinal permeability was determined in rats receiving colchicine 0.5 +/- 0.15 mg day-1 in drinking water (30 mg L-1) for periods up to 23 days.